Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eledon Pharmaceuticals, Inc. (ELDN) had Return on Tangible Equity of -38.85% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-39.02M |
|
-- |
|
-- |
|
$21.18M |
|
$-21.18M |
|
$-17.84M |
|
$-39.02M |
|
$-39.02M |
|
$-39.02M |
|
$-39.02M |
|
$-39.02M |
|
$-39.02M |
|
$-21.18M |
|
$-21.18M |
|
112.42M |
|
112.42M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$113.57M |
|
-- |
|
$33.09M |
|
$146.67M |
|
$13.46M |
|
-- |
|
$32.75M |
|
$46.21M |
|
$44.76M |
|
$100.46M |
|
$100.46M |
|
75.85M |
|
| Cash Flow Statement Financials | |
$-22.61M |
|
$5.96M |
|
-- |
|
$22.81M |
|
$6.15M |
|
$-16.66M |
|
$2.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-22.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-87.18% |
|
|
Return on Tangible Equity |
-38.85% |
-26.61% |
|
-38.85% |
|
$1.32 |
|
$-0.20 |
|
$-0.20 |
|